Arie Belldegrun - 16 Sep 2021 Form 3/A - Amendment Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Director
Signature: /s/ Karen Tepichin, Attorney-in-fact
Issuer symbol: DNA
Transactions as of: 16 Sep 2021
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 28 Mar 2022, 17:30:36 UTC
Date Of Original Report: 20 Sep 2021
Previous filing: 23 Jun 2021
Next filing: 14 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DNA	Class A Common Stock						18,741	16 Sep 2021	Direct
holding	DNA	Class A Common Stock						500,000	16 Sep 2021	By Bellco Legacy LLC	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	DNA	Warrants							16 Sep 2021	Class A Common Stock	3,748	$11.50	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects shares of Class A Common Stock acquired in a pro rata distribution in-kind, the acquisition of which was exempt pursuant to Rule 16a-9.
F2	Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.